Susceptibility to Tigecycline of Multiresistant Bacteria at Ibn Rochd University Hospital-Casablanca

A descriptive prospective study was conducted between 2015 and 2017 at the Microbiology laboratory of the Casablanca University Hospital Center to study the Tigecycline susceptibility of isolated multi drug resistant bacteria (MDRB): Imipenem-resistant Acinetobacter baumannii (IRAB), ESBL+/- Carbapenemase-producing enterobacteria (ESBLE), Meticillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE). Antibiotic sensitivity tests were performed by diffusion method and those for Tigecycline by E-test strips according to EUCAST / CA-SFM. Breakpoints of interpretation of Tigecycline sensitivity were according to the FDA. A total of 692 MDRB strains were studied. The Tigecycline resistance rate was 33.9% (25.3% I, 8.6% R). For IRAB, it was 46% (30.5% I, 15.5% R), for ESBLE 27.9% (100% I), for MRSA 10% (100% R) and no VRE was resistant to Tigecycline. However, as EUCAST has not determined breakpoints for the in vitro thresholds of A.baumannii concerning Tigecycline, conclusions should not be formally established as to its sensibility.